VivoSeq
Oncology

Advanced Head and Neck Cancer

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Advanced Head and Neck Cancer is an early-stage landscape with 0 programs across 3 companies. The most active players are Eastern Cooperative Oncology Group, Radiation Therapy Oncology Group, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

0 programs

PreclinicalRadiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

45

clinical trials

Completed33 · 73%
Terminated7 · 16%
Withdrawn2 · 4%
Active, not recruiting1 · 2%
Recruiting1 · 2%
Unknown status1 · 2%

Clinical Trials

Trial Activity

45 trials

A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07457346·76 enrolled
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT04533750·21 enrolled
Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer
Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003592·230 enrolled
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00935961·18 enrolled
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
Completed·UUniversity of Zurich·Phase 2·NCT01435252·68 enrolled
Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 3·NCT02918955·65 enrolled
Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer
Completed·SSwiss Cancer Institute·Phase 3·NCT00002654·224 enrolled
Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 3·NCT00006481
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1·NCT00405405·13 enrolled
Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer
Completed·UUniversity of Tennessee·Phase 2·NCT00003580
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Completed·National Cancer Institute (NCI)·Phase 2/3·NCT03258554·196 enrolled
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Completed·—·Phase 2·NCT00462735·33 enrolled
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer
Completed·WWashington University School of Medicine·Phase 2·NCT00736944·30 enrolled
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
Completed·UUniversity of Colorado, Denver·Phase 1·NCT01758731·17 enrolled
Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
Completed·CCancer Research UK·Phase 3·NCT00002476
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)